Metypred (Methylprednisolone Sodium Succinate)

Metypred, a systemic glucocorticoid, is indicated for several inflammatory and immune‑mediated conditions.

• Acute asthma or COPD exacerbations: reduces airway inflammation, improves airflow and relieves symptoms.
• Severe allergic reactions (including anaphylaxis): rapidly suppresses hypersensitivity response and prevents progression.
• Rheumatoid arthritis and other inflammatory rheumatic diseases: decreases joint inflammation, pain and swelling.
• Dermatologic inflammatory conditions (e.g., severe eczema, psoriasis): controls skin inflammation and accelerates lesion resolution.
• Autoimmune disorders (e.g., systemic lupus erythematosus, vasculitis): modulates immune activity to limit tissue damage.

• Methylprednisolone Sodium Succinate diffuses into cells and binds intracellular glucocorticoid receptors. The resulting complex translocates to the nucleus, where it interacts with glucocorticoid response elements on DNA, altering transcription of numerous genes. This down‑regulates pro‑inflammatory cytokines, inhibits leukocyte migration, and suppresses immune‑cell activation, producing potent anti‑inflammatory and immunosuppressive effects.

Systemic exposure to methylprednisolone may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Elevated blood glucose
• Increased blood pressure
• Insomnia or mood changes
• Fluid retention

Serious or Rare Side Effects

• Severe infections or sepsis
• Adrenal suppression on abrupt discontinuation
• Osteonecrosis (bone death)
• Life‑threatening allergic reactions (anaphylaxis)

When prescribing Metypred, clinicians should consider several safety measures.

• Assess for active infections before initiating therapy.
• Monitor blood glucose and blood pressure regularly during treatment.
• Taper the dose gradually when discontinuing after prolonged use.
• Use with caution in patients with known osteoporosis or fracture risk.
• Avoid in patients with systemic fungal infections unless benefits outweigh risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metypred can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may increase steroid exposure.
• Live vaccines (e.g., measles, varicella) due to immunosuppression.
• Anticoagulants such as warfarin, which may have enhanced anticoagulant effect.
• Systemic antifungal agents (e.g., itraconazole) that can raise steroid levels.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) increasing risk of gastrointestinal bleeding.
• Antidiabetic agents, as steroids may raise blood glucose requiring dose adjustment.
• Antihypertensive medications, because fluid retention may blunt their effect.
• Diuretics, which may potentiate electrolyte disturbances.